The wave of Covid-induced dividend cuts is forcing many British investors to re-evaluate their saving strategies. According to stockbroker AJ Bell, total dividend payments for 2020 are on course to be the lowest in six years – £63bn – with cuts estimated at £31.6bn. With £26.5bn – more than 80% – of the cuts coming from FTSE 100 firms, the current crisis has reminded investors of the importance of diversification. Historically, savers have relied on the blue-chip index, but there are plenty of income-generating small caps with more consistent payout policies.
Many investors assume that smaller companies are always more vulnerable to economic difficulties, but we look for companies dominant in niche markets that are relatively insulated from macro dynamics. Investors’ instinctive aversion to smaller companies means they can be neglected and thus offer us an attractive entry point. They are currently trading at a substantial discount to large caps.
A fantastic record of payout increases
Bioventix (Aim: BVXP), for instance, is a research-and-development company focused on producing antibodies for clinical diagnostics and pharmaceutical research. Thanks to its highly cash-generative business model, the £220m market cap company – which has a dividend yield of 2% – has a fantastic record of dividend increases: a 30% compound annual growth rate (CAGR) over five years. This means if you bought the shares on 1 July 2014, more than 80% of your original cost would have been returned in dividends and your capital would have appreciated by 750%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Another little-known consistent dividend growth story is Anpario (Aim: ANP), an £85m market-cap natural animal-feed additive producer for global agriculture and aquaculture markets. The company offers a 2.3% dividend yield and has seen 12% dividend-per-share CAGR over the past five years. The dividend cover is well over two times.
Securing new income streams
While hunting down the market-cap spectrum can unearth dividend payers to alleviate the income drought, investors should not stay fixated on current payouts. Now is the time to focus on high-quality, promising businesses with the capacity to grow and pay dividends in the future.
The Baronsmead venture capital trust portfolios blend earlier-stage unquoted businesses, which provide access to capital growth, with more stable income-generating Aim stocks. This unique approach allows us to identify the dividend payers of the future while maintaining a regular income stream.
By taking smaller initial stakes in a broad range of early-stage companies we can manage downside risk as we assess the business growth potential. We then focus on the best companies, providing further capital and expertise. If a company scales up and becomes a listed reliable dividend payer, we can also invest in it through our other open-ended equity funds.
Ideagen (Aim: IDEA) is one company we have our eye on. The market-leading provider of governance, risk and compliance software already pays a dividend and, as it matures, will form an increasing proportion of our overall return. This is a stock we invested in originally at 19p in 2013. It now costs 172.5p.
-
8 of the best converted properties for sale nowThe best converted properties for sale – from an apartment in the former Hartley’s Jam factory on London’s Southbank, to a converted 18th-century mill in Itteringham, Norfolk
-
How taking a two-year career break could leave a £26k hole in your pensionCareer breaks are increasingly common but it is important to take steps to protect your pension, as gaps compound over time
-
Will Comstock crash – or soar?Opinion The upside for Comstock, a solar panel-recycling and biomass-refining group, dwarfs the downside, says Dominic Frisby.
-
'As AGMs go digital, firms must offer a new form of scrutiny for shareholders'Opinion Technology has rendered big AGM meet-ups obsolete, but the board still needs to be held to account, says Matthew Lynn
-
Unilever braces for inflation amid tariff uncertainty – what does it mean for investors?Consumer-goods giant Unilever has made steady progress simplifying its operations. Will tariffs now cause turbulence?
-
'Technology will determine tomorrow’s top stocks in emerging markets'Opinion John Citron, investment manager of the JPMorgan Emerging Markets Investment Trust, tells us where he’d put his money
-
Two ways to tap into monopoly profits from airportsMost investors can’t get their hands on airports. Here are two ways you can
-
Three British mid-caps that could make 'attractive' investmentsOpinion Charles Luke, manager of the Murray Income Trust, highlights three UK-listed mid-cap companies, as he tells us where he'd put his money
-
Fat profits: should you invest in weight-loss drugs?The latest weight-loss treatments could transform public health and the world economy. Should you invest?
-
How investors could profit from Ramsden Holdings' four-part growth strategyRamsdens Holdings offers a diversified set of financial and retail services and a juicy yield, says Dr Michael Tubbs
